0:16:38 · Brian Peterson, Raymond James · AI search
How did AI search build this year and what could it do for Doximity's positioning into 2027?
Jeff Tangney said top-level meetings with pharma executives are going well, a survey shows pharma marketers favoring Doximity over paid search, and biddable auction-based buying will start with pilot clients. — Jeff Tangney
0:19:17 · Brian Peterson, Raymond James · AI compute costs
Can you unpack the AI compute efficiency measures?
Management said cost of revenue grew at less than half the rate of prompt volume, helped by multi-model use, pre-bought capacity and its proprietary harness. — Jeff Tangney, Matt Sonnenfeld
0:21:38 · Michael Cherney, Leerink Partners · UpToDate partnership
Why was UpToDate the right partner for Doximity's AI?
Jeff Tangney called UpToDate the most used and trusted point-of-care reference, with content no frontier model has, and said both firms have many shared health-system clients. — Jeff Tangney
0:30:00 · Michael Cherney, Leerink Partners · Operating leverage
What builds confidence in operating leverage beyond the efficiencies already cited?
Matt Sonnenfeld said engagement comes before monetization, nothing in the AI investment or early AI search suggests a worse margin profile, and scaling AI search in FY28 should lift incremental margins. — Matt Sonnenfeld
0:31:45 · Ryan Daniels, William Blair · Cannibalization
Is AI search cannibalizing other pharma sales or is it incremental?
Jeff Tangney said it is mostly incremental, bought by separate search teams, though not provably 100 %, and Matt Sonnenfeld said all major product categories grew. — Jeff Tangney, Matt Sonnenfeld
0:34:08 · Ryan Daniels, William Blair · AI governance
How does tighter health-system AI governance affect Doximity's advantage?
Jeff Tangney said health systems are moving past an unregulated phase of AI, citing a Johns Hopkins data incident, and that Doximity has privacy agreements with over 300 enterprise clients. — Jeff Tangney
0:37:12 · Elizabeth Anderson, Evercore ISI · Customer ramp
How are smaller pharma customers ramping with AI search compared with the top 20?
Jeff Tangney said smaller accounts move faster but are being saved for the biddable tool, and Matt Sonnenfeld said available conditions have more than doubled on customer demand. — Jeff Tangney, Matt Sonnenfeld
0:40:20 · Ryan McDonald, Needham & Company · EHR integration
What usage uplift comes from EHR integration, as at New York Presbyterian?
Jeff Tangney said patient context roughly doubles usage, but simply adding a button in an EHR drives less usage than expected without training. — Jeff Tangney
0:42:50 · Ryan McDonald, Needham & Company · UpToDate distribution
Can UpToDate help bring Doximity into health systems?
Jeff Tangney said UpToDate is in virtually every U.S. health system and the partnership is multi-year, but he had no go-to-market announcement. — Jeff Tangney
0:43:58 · Scott Schoenhaus, KeyBanc · Medical-legal review
How long does medical-legal review take and how does AI search revenue ramp after it?
Jeff Tangney said review can take many months, as with the video product, and Matt Sonnenfeld said guidance assumes a gradual ramp through calendar 2027. — Jeff Tangney, Matt Sonnenfeld
0:46:54 · Scott Schoenhaus, KeyBanc · Growth outlook
What does the roughly 6 % growth rate say about market growth versus Doximity's own?
Matt Sonnenfeld said it reflects the beginnings of reacceleration but is cautious until the upfront season ends, and Jeff Tangney expects a somewhat better market next year. — Matt Sonnenfeld, Jeff Tangney
0:48:32 · Richard Close, Canaccord Genuity · Go-to-market
Is there a separate sales force for AI search and is it bundled into upfront contracts?
Jeff Tangney said AI search experts overlay the existing sales team, and the work is usually under a separate statement of work from the same master agreement. — Jeff Tangney
0:49:48 · Jessica Tadson, Piper Sandler · Monetization
How is AI search monetized: enterprise subscriptions, pharma bookings or both?
Matt Sonnenfeld said the eight-figure bookings are primarily pharma advertising, while health systems pay a nominal amount as part of the broader workflow suite. — Matt Sonnenfeld
0:51:41 · Jessica Tadson, Piper Sandler · Pharma ROI
What are early thoughts on ROI for pharma content in AI search versus the core business?
Management said it is too early, but expects ROI as strong as other products or better, with AI signals also improving the rest of the portfolio. — Matt Sonnenfeld
0:53:12 · Destiny Jackson, JPMorgan · Net revenue retention
What drove lower net revenue retention and how can expansion reaccelerate?
Matt Sonnenfeld said retention follows revenue growth and he expects reacceleration, and Jeff Tangney pointed to AI search, a stronger core portfolio and a better market. — Matt Sonnenfeld, Jeff Tangney
0:55:12 · Destiny Jackson, JPMorgan · Customer count
Why did the count of customers above $500,000 come down?
Matt Sonnenfeld said the second quarter is seasonally weaker for that metric because there is less upsell activity. — Matt Sonnenfeld
0:56:27 · Alan Lutz, Bank of America · Competition
How is the competitive landscape evolving in AI search for pharma and health systems?
Jeff Tangney said pharma interest in incremental spend with Doximity is at a high while paid search is at a low, and Doximity now operates as both a media and a search company. — Jeff Tangney
0:58:25 · Alan Lutz, Bank of America · Investment vs margins
How does Doximity weigh high-ROI investment in AI search against keeping margins above 50 %?
Matt Sonnenfeld said the full-year margin guide already builds in investment, and efficiency gains let Doximity keep playing offense while generating strong incremental margins. — Matt Sonnenfeld
1:01:06 · Ryan Halstead, RBC Capital Markets · Pharma budgets
How healthy are HCP marketing budgets going into the upfront season?
Management described a more stable environment than last year as policy uncertainty eases, though not a major reacceleration. — Matt Sonnenfeld, Jeff Tangney